Enabling Direct-To-Patient (DtP) Drug Supply

At S-CLINICA we have been developing sophisticated IRT systems and Drug supply management tools used by innovative pharma and biotech clients for over the 23 years. Our focus on these core service offerings has enabled us to develop deep domain expertise in patient and drug supply management, helping clients avoid potential pitfalls. Clinical trials are becoming more patient centric, with increasing use of virtual and hybrid trials, electronic patient reported outcome (ePRO) data collection through patients own devices, resulting in more requests for studies with direct-to-patient drug shipping for patients who aren’t able to leave home to attend clinical sites, or just to reach more, and increasingly diverse patient population who cannot or will not travel. In today’s COVID environment, with some patients unable to access hospitals and clinics or even reluctant to use public transport, patients centricity means been able to supply Investigational medicinal products (IMPs) directly to a patients home, with trial medication despatched from the clinical site, from a dedicated depot or in some countries from Pharmacies ( e.g., Denmark). In addition the technology underpinning this must also be sophisticated enough to be able perform the following tasks;

• Account for Unblinding Scenarios
• Maintain Patient Privacy
•  Handle Temperature Deviations
• Handle Labelling requirements for just in time delivery
• Flexible enough to account for individual patient challenges
• Perform drug accountability and drug destruction
• Flexible supply modelling
• Patient training